Medical Devices Canada

Canada Polygenic Risk Scores Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Canada Polygenic Risk Scores Market Industry Trends and Forecast to 2034: Segmented by (Condition, User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Canada · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $15.2 Mn Placeholder estimate
Estimate 2025 $17.9 Mn 8.6% of the global market
Projected 2034 $77.5 Mn 333.5% Adds $59.6 Mn over 9 forecast years
CAGR 2025–2034 17.7% Faster than 92% of 173 Medical Devices markets here
Key players 5
  • Canada is 8.56% of the global market.
  • In North America, the largest is US at $77.2 Mn.
  • Fastest growing: Canada (this report) at 17.7% a year.
  • Canada ranks 2nd of 2 by size in North America.

Market size projection

Canada

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$59.6 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Polygenic Risk Scores Market market size by year, Canada
YearMarket sizeChange that yearSince 2025
2024 (estimate) $15.2 Mn — —
2025 (base) $17.9 Mn +$2.7 Mn —
2026 (forecast) $21.0 Mn +$3.2 Mn +17.7%
2027 (forecast) $24.8 Mn +$3.7 Mn +38.5%
2028 (forecast) $29.1 Mn +$4.4 Mn +63.1%
2029 (forecast) $34.3 Mn +$5.2 Mn +91.9%
2030 (forecast) $40.4 Mn +$6.1 Mn +125.9%
2031 (forecast) $47.5 Mn +$7.1 Mn +165.9%
2032 (forecast) $55.9 Mn +$8.4 Mn +212.9%
2033 (forecast) $65.8 Mn +$9.9 Mn +268.3%
2034 (forecast) $77.5 Mn +$11.7 Mn +333.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Canada Polygenic Risk Scores Market Analysis at a glance
Market size, 2025$17.9 Mn placeholder estimate
Forecast, 2034$77.5 Mn placeholder estimate
Growth (CAGR), 2025–203417.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsCondition and user (see all)
Key playersGenomics plc, Allelica, Myriad Genetics, Inc., 23andMe, Color Health (see all)
Regulator in CanadaHealth CanadaSource: Health Canada. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Canada Polygenic Risk Scores Market Analysis Executive Summary

Polygenic risk scores combine many small genetic effects to estimate a person's risk of common diseases such as heart disease and diabetes.

Key segments of the polygenic Risk Scores market include condition (Cardiovascular Disease, Cancer and Diabetes) and user (Clinicians, Consumers and Researchers).

Bar chart: Canada Polygenic Risk Scores market size, 2024–2034, placeholder estimates. $15.2 Mn in 2024, $17.9 Mn in 2025 and $77.5 Mn in 2034, 17.7% CAGR.
Canada Polygenic Risk Scores market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Canada Polygenic Risk Scores Market Dynamics

Market Growth Drivers

The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the polygenic Risk Scores market.

Opportunity

Routine use of genomics in screening, pharmacy and primary care gives the polygenic Risk Scores market large room to grow.

Market Restraints

Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the polygenic Risk Scores market.

Competitive Landscape for Polygenic Risk Scores Market in Canada

The polygenic Risk Scores market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Polygenic Risk Scores Market in Canada

Polygenic Risk Scores in Canada: rules and payment

Health Canada licenses Class II, III and IV medical devices; Class I devices are sold by companies that hold an establishment licence.⁠[1] Each province and territory runs public health insurance under the Canada Health Act, which covers medically necessary hospital and doctor services.⁠[2]

[1] Health Canada. Checked 14 Nov 2026.

[2] Health Canada. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how polygenic Risk Scores products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Canada.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Polygenic Risk Scores right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Polygenic Risk Scores in context

Canada compared

  • Health spending per person: 6,378 US$ per person (2024). World: 1,317 US$ per person (2023).[1]
  • Doctors: 2.82 per 1,000 people (2023). World: 1.86 per 1,000 people (2022).[2]
  • People aged 65 and over: 20.3% of people (2025). World: 10.4% of people (2025).[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Polygenic Risk Scores market in Canada?
Placeholder estimate: about $17.9 Mn in 2025, rising to about $77.5 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Polygenic Risk Scores market in Canada growing?
Placeholder estimate: about 17.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Polygenic Risk Scores market report cover?
The report splits the market by condition (Cardiovascular Disease, Cancer, Diabetes, Psychiatric Conditions) and user (Clinicians, Consumers, Researchers).
Who are the key players in the Polygenic Risk Scores market?
Key players include Genomics plc, Allelica, Myriad Genetics, Inc., 23andMe and Color Health.
What is driving the Polygenic Risk Scores market?
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the polygenic Risk Scores market.
Who regulates Polygenic Risk Scores in Canada?
Health Canada licenses Class II, III and IV medical devices; Class I devices are sold by companies that hold an establishment licence. Source: Health Canada. Checked 14 Nov 2026.
How is healthcare paid for in Canada?
Each province and territory runs public health insurance under the Canada Health Act, which covers medically necessary hospital and doctor services. Source: Health Canada. Checked 14 Nov 2026.
How much research is published on Polygenic Risk Scores?
PubMed lists 3,814 papers on Polygenic Risk Scores added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in Canada

See all

Related on genomics and diagnostics and lab testing

See the topic